[Production and assessing release of imipramine and magnesium from tablets].
BACKGROUND
In the pharmaceutical technology there is a trend to produce tablets composed of several medicinal substances to increase therapeutic effect and reduce the frequency of drug administration. In the literature there are reports concerning pharmacological studies in which a potentiation of the effects has been observed after a co-administration of antidepressant imipramine and magnesium. Currently, there is no formulation on the market comprising imipramine and magnesium, therefore, it was decided to produce uncoated tablets. In order to prepare the tablets by direct compression, it was necessary to select suitable excipients.


OBJECTIVE
The aim of the study was to elaborate the composition and to prepare the tablets with imipramine and magnesium, as well as to assess the quality of the tablets by physical characteristics and by the release study of the active substances.


METHODS
In order to prepare the tablets, compositions of different polymers and other excipients were added. The tablets were produced by direct compression method in a tablet press. Physical properties of the obtained tablets and the release of the active substances into an acidic medium in a paddle apparatus were tested. The contents of imipramine and magnesium were determined by different methods: spectrophotometrically and atomic absorption spectrometry, respectively.


RESULTS
The composition of excipients necessary to produce tablets comprising imipramine and magnesium was established. All of prepared tablets were in compliance with the pharmacopoeial requirements. The release tests showed that above 80% of imipramine was released within 20-35 min and 80-76% of magnesium up to 45 min from the composed tablets and one-ingredient tablets, respectively.


CONCLUSIONS
The compositions of excipients for tablets consisting of imipramine and magnesium were presented. The active substances were released within 45 min in the acidic medium, and the administration of these substances in the composed tablets did not affect pharmaceutical availability.
Katedra i Zakład Farmacji Stosowanej, Wydział Farmaceutyczny, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Regina
R
Kasperek
Katedra i Zakład Farmacji Stosowanej, Wydział Farmaceutyczny, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Łukasz
Ł
Zimmer
Katedra i Zakład Żywności i Żywienia, Wydział Farmaceutyczny, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Agnieszka
A
Szalast-Pietrzak
Katedra i Zakład Żywności i Żywienia, Wydział Farmaceutyczny, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Zbigniew
Z
Marzec
Katedra i Zakład Farmacji Stosowanej, Wydział Farmaceutyczny, Uniwersytet Medyczny w Lublinie, Lublin, Polska.
Ewa
E
Poleszak
D000928:Antidepressive Agents / Q000008:administration & dosage / Q000737:chemistry; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004339:Drug Compounding / Q000379:methods*; D005079:Excipients / Q000737:chemistry; D007099:Imipramine / Q000008:administration & dosage* / Q000737:chemistry*; D008274:Magnesium / Q000008:administration & dosage* / Q000737:chemistry*; D011108:Polymers / Q000737:chemistry; D012995:Solubility; D013607:Tablets / Q000138:chemical synthesis* / Q000737:chemistry*; D013678:Technology, Pharmaceutical
D000928:Antidepressive Agents; D003692:Delayed-Action Preparations; D005079:Excipients; D011108:Polymers; D013607:Tablets; D008274:Magnesium; D007099:Imipramine